WCLC News & Analysis

AbbVie (ABBV) Presents Lung Cancer Data at WCLC 2026 Conference

AbbVie (ABBV) presented lung cancer data at the World Conference on Lung Cancer (WCLC) 2026, including results for ABBV-1480, which achieved a 90.0% objective response rate in squamous NSCLC and 75.9% in non-squamous NSCLC when combined with platinum-based chemotherapy. Safety data for ABBV-706 showed nausea in 35.8% of patients and grade 3+ pneumonitis or interstitial lung disease in 1.7% of patients.